Display options
Cite
Sosale B, Sosale A, Bhattacharyya A. Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes. Diabetes Ther. 2016;7(4):765-776doi: 10.1007/s13300-016-0204-9.
Sosale, B., Sosale, A., & Bhattacharyya, A. (2016). Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders, 7(4), 765-776. https://doi.org/10.1007/s13300-016-0204-9
Sosale, Bhavana, et al. "Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 7,4 (2016): 765-776. doi: https://doi.org/10.1007/s13300-016-0204-9
Sosale B, Sosale A, Bhattacharyya A. Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes. Diabetes Ther. 2016 Dec;7(4):765-776. doi: 10.1007/s13300-016-0204-9. Epub 2016 Oct 19. PMID: 27761881; PMCID: PMC5118242.
Copy Download .nbib Format: NLM
Share it on

Diabetes Ther. 2016 Dec;7(4):765-776. doi: 10.1007/s13300-016-0204-9. Epub 2016 Oct 19.

Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Bhavana Sosale, Aravind Sosale, Arpandev Bhattacharyya

Affiliations

  1. Diacon Hospital 360, 19th Main, 1st Block, Rajajinagar, Bangalore, Karnataka, 560010, India. [email protected].
  2. Diacon Hospital 360, 19th Main, 1st Block, Rajajinagar, Bangalore, Karnataka, 560010, India.
  3. Shivajoyti, 3366, 13th Main, Indiranagar, Bangalore, Karnataka, 560008, India.

PMID: 27761881 PMCID: PMC5118242 DOI: 10.1007/s13300-016-0204-9

Abstract

INTRODUCTION: Dapagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, is a promising drug approved for the treatment of type 2 diabetes mellitus (T2DM). However, its cost is an obstacle for use in developing countries like India. Thus, we aimed to analyse the impact on the cost of insulin therapy after adding dapagliflozin for patients using insulin in real-world clinical practice.

METHODS: This retrospective chart review study included patients with uncontrolled T2DM previously on maximum doses of OADs and insulin therapy, initiated on dapagliflozin. Parameters measured were: HbA1c, changes in weight and insulin dosage, frequency and cost, at baseline and after 3 months of adding dapagliflozin 10 mg. Hospital records of patients attending the diabetes outpatient departments at the study centres were scrutinised to identify eligible patients. A treat-to-target approach was used to make changes in the insulin dosages and regimen. The cost of insulin was calculated based on the total daily dose, cost per unit based on the formulation and insulin delivery device. Statistical analysis included descriptive and inferential methods.

RESULTS: Overall, 70 patients meeting the inclusion criteria were included in the study. The mean age of patients and duration of T2DM were 52.6 ± 10 and 12 ± 5 years respectively. The mean reduction in HbA1c and weight was 2.1 ± 1% (p < 0.01) and 2.4 ± 1 kg (p < 0.01) respectively. Genital mycotic infections were reported in two (2.8%) patients. The mean reduction in the total daily dose of insulin was 9.5 ± 6 units. A significant reduction in the daily insulin requirement (19.87%, p < 0.01) was observed. The cost of insulin decreased by 22.3% or 17.8 ± 15 INR per day ($0.27 ± 0.22 per day) and the frequency of insulin shots administered per day decreased significantly (p < 0.01). In 12.8% and 2.8% of patients the frequency of administration of insulin decreased by one and two injections per day respectively.

CONCLUSIONS: Reduction in HbA1c and body weight along with minimal side effects was observed. Addition of dapagliflozin reduced the insulin daily dose requirement and cost of insulin therapy in these patients.

FUNDING: Diacon Hospital, Bangalore, India.

Keywords: Dapagliflozin; Dosage; HbA1c; Health economics; Insulin cost; SGLT2 inhibitors; Sodium glucose co-transporter 2 inhibitors; Type 2 diabetes; Weight reduction

References

  1. Ann Intern Med. 2013 Aug 20;159(4):262-74 - PubMed
  2. JAMA. 2000 Apr 5;283(13):1695-702 - PubMed
  3. Diabetes Care. 2015 Jan;38(1):140-9 - PubMed
  4. Diabetes Obes Metab. 2012 Jun;14(6):539-45 - PubMed
  5. Diabetologia. 2013 Dec;56(12):2582-92 - PubMed
  6. BMC Endocr Disord. 2016 Jul 08;16(1):39 - PubMed
  7. Diabetes. 1995 Nov;44(11):1249-58 - PubMed
  8. Diabetes Care. 1999 Jul;22(7):1125-36 - PubMed
  9. Diabet Med. 2012 Jul;29(7):855-62 - PubMed
  10. Diabetes Obes Metab. 2014 May;16(5):457-66 - PubMed
  11. Diabetes Obes Metab. 2014 Feb;16(2):124-36 - PubMed
  12. Am J Prev Med. 2002 May;22(4 Suppl):15-38 - PubMed
  13. J Diabetes Investig. 2016 Jul;7(4):555-64 - PubMed
  14. Diabetes Care. 2014 Jan;37 Suppl 1:S14-80 - PubMed
  15. Patient Educ Couns. 2007 Sep;68(1):10-5 - PubMed
  16. Diabetes Obes Metab. 2013 Dec;15(12):1154-60 - PubMed
  17. Health Policy Plan. 2006 Sep;21(5):402-8 - PubMed
  18. Endocr Rev. 2011 Aug;32(4):515-31 - PubMed
  19. Diabetes Care. 2011 Sep;34(9):2015-22 - PubMed
  20. Cardiovasc Diabetol. 2015 Oct 17;14:142 - PubMed
  21. Diabetes Care. 2014 Jul;37(7):1815-23 - PubMed
  22. Curr Med Res Opin. 2011 Nov;27 Suppl 3:13-20 - PubMed
  23. Indian J Med Res. 2007 Mar;125(3):473-82 - PubMed
  24. Ann Intern Med. 2012 Mar 20;156(6):405-15 - PubMed
  25. Diabetes Res Clin Pract. 2014 Mar;103(3):373-81 - PubMed
  26. N Engl J Med. 2016 Jul 28;375(4):323-34 - PubMed
  27. Diabetes Care. 2007 Aug;30(8):1979-87 - PubMed
  28. N Engl J Med. 2015 Nov 26;373(22):2117-28 - PubMed
  29. Endocr Pract. 2015 Apr;21(4):438-47 - PubMed
  30. Diabetes Res Clin Pract. 2000 Apr;48(1):37-42 - PubMed
  31. Int J Clin Pract. 2013 Dec;67(12):1267-82 - PubMed
  32. Diabetes Metab Syndr Obes. 2015 Nov 09;8:543-54 - PubMed
  33. J Med Econ. 2013 Nov;16(11):1357-65 - PubMed
  34. Postgrad Med. 2016 Jan;128(1):124-36 - PubMed
  35. Clin Drug Investig. 2014 Feb;34(2):135-46 - PubMed
  36. Lancet Diabetes Endocrinol. 2015 May;3(5):356-66 - PubMed
  37. Global Health. 2014 Dec 02;10:80 - PubMed
  38. Diabetes Care. 2015 Mar;38(3):403-11 - PubMed

Publication Types